M MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U. S. Mission and ValuesOur mission is to use our proprietary technologies and breakthrough discoveries to treat diseases and to create a better world. Our MannKind Values of Integrity, Leadership, Communications, and Teamwork provide the foundation of our culture. We have two physical locations in the United States.